Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type

Completed

• Conditions: Uncommon Pathological Types of Lung Cancer

• Registration Number: NCT05023837
• Lead Sponsor: Hunan Province Tumor Hospital

Brief Summary

This study was designed to explore the efficacy and safety of immune checkpoint inhibitor for advanced uncommon pathological types of lung cancer whether or not it is accompanied by a driver mutationin the real world. Through retrospective collection of clinical data of patients with uncommon pathological types of lung cancer.The patients who are treated with immunosuppressive agents are screened out, and they are divided into immune combination therapy or immune monotherapy, and further evaluate whether there is a difference in efficacy between the two.

Detailed Description

This is a research project involving patients in Medical Oncology Department of Affiliated Cancer Hospital of Xiangya School of Medicine Central South University. Retrospective study of 40 patients with advanced uncommon pathological types of lung cancer and observe the efficacy and safety of immune checkpoint inhibitor regimen in the real world. The patients who are treated with immunosuppressive agents are screened out, and they are divided into immune combination therapy or immune monotherapy, and further evaluate whether there is a difference in efficacy between the two. Statistical analysis is used to compare the differences between the two treatments, so that patients can better choose treatment strategies.

Study Timeline

• Study Start: 2018-03-02
• Primary Completion: 2021-08-02
• Study Completion: 2021-08-03
• Study First Submitted: 2021-08-21
• Study First Submitted QC: 2021-08-21
• Study First Posted: 2021-08-27
• Status Verified: 2022-01
• Last Update Submitted: 2022-01-22
• Last Update Posted: 2022-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• 18，Advanced uncommon pathological types of lung cancer by histopathology whether or not it is accompanied by a driver mutation Treatment Plan is pembrolizumab 200mg iv q21d

Exclusion Criteria

• Patients received antitumor treatment before Patients with contraindication of chemotherapy Pregnant or breast feeding women

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PFS	may 2019- may 2021	progression survival time

Secondary Outcome Measures

Name	Time	Method
OS	may 2019- may 2021	over survival time

Trial Locations

Locations (1)

Hunan Cancer Hospital; 🇨🇳 Changsha, Hunan, China